The Revivent-TC™ TransCather Ventricular Enhancement System extends the Less Invasive Ventricular Enhancement™ (LIVE™) procedure, pioneered by BioVentrix as an alternative to conventional surgical ventricular restoration (SVR), by enabling a closed-chest endovascular approach. Placement of the Revivent-TC System is done without sternotomy or ventriculotomy, so the need for cardiopulmonary bypass is eliminated. The proprietary TransCatheter delivery system enables volume reduction of the left ventricle (LV) via placement of anchors designed to exclude scarred myocardial tissue from the left ventricle while also restoring its more natural conical shape. Recent peer-reviewed studies have found that LV volume is the best predictor of survival in ischemic cardiomyopathy patients.
The LIVE™ procedure is based upon a well-defined law of physics called the Laplace's law, which describes the relationship between the radius and pressure of the LV, and the resulting LV wall tension. Increased wall tension is the underlying cause of LV enlargement, worsening heart failure symptoms and ultimately patient death. Conversely, reducing wall tension prevents further LV enlargement and stops the progression of the disease.
The Revivent-TC™ Transcatheter Ventricular Enhancement System is uniquely designed to reduce wall tension by directly reducing the LV radius, which in turn decreases wall tension and interrupts the ongoing destructive process of ischemic heart failure. Restoring the LV to its more optimal, conical geometry, enhances the performance of the remaining myocardium.